Quick Answer
IN8BIO, INC. reported Stockholders Equity of $27.56 million for the year ending 2025.
- IN8BIO, INC. showed an increase of +90.3% in Stockholders Equity from 2024 to 2025.
- This data is from IN8BIO, INC.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$10.72 million | Q2 2020: -$13.57 million | Q3 2020: -$14.88 million | Q1 2021: -$18.58 million | Q2 2021: -$21.24 million | Q3 2021: $43.04 million | Q1 2022: $32.84 million | Q2 2022: $26.57 million | Q3 2022: $29.56 million | Q1 2023: $16.79 million | Q2 2023: $21.80 million | Q3 2023: $17.76 million | Q1 2024: $17.53 million | Q2 2024: $13.62 million | Q3 2024: $8.59 million | Q1 2025: $13.88 million | Q2 2025: $15.24 million | Q3 2025: $13.19 million.
- Over the full 7 years of available data (2019 to 2025), IN8BIO, INC.'s Stockholders Equity has grown by 398.2%.
- Historical annual values: Fiscal year 2025: $27.56 million | Fiscal year 2024: $14.48 million | Fiscal year 2023: $24.94 million | Fiscal year 2022: $22.73 million | Fiscal year 2021: -$38.18 million | Fiscal year 2020: -$16.58 million | Fiscal year 2019: -$9.24 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: